Brokers Set Expectations for ICON Public Q1 Earnings

ICON Public Limited (NASDAQ:ICLR) – William Blair issued their Q1 2026 earnings estimates for shares of ICON Public in a report released on Thursday, February 20th. William Blair analyst M. Smock expects that the medical research company will earn $3.45 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.38 per share. William Blair also issued estimates for ICON Public’s Q2 2026 earnings at $3.66 EPS, Q3 2026 earnings at $3.91 EPS, Q4 2026 earnings at $4.19 EPS and FY2026 earnings at $15.20 EPS.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion.

Several other research analysts have also recently weighed in on ICLR. JPMorgan Chase & Co. dropped their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Robert W. Baird cut their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Truist Financial decreased their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Citigroup cut their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a research note on Wednesday, January 15th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $281.00.

ICON Public Stock Performance

Shares of ICLR opened at $201.39 on Monday. The company has a market cap of $16.61 billion, a price-to-earnings ratio of 21.13, a P/E/G ratio of 1.86 and a beta of 1.19. The business’s fifty day simple moving average is $202.90 and its two-hundred day simple moving average is $244.47. ICON Public has a 12 month low of $181.51 and a 12 month high of $347.72. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36.

Hedge Funds Weigh In On ICON Public

Several institutional investors have recently bought and sold shares of the stock. Arkadios Wealth Advisors boosted its holdings in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 62 shares during the last quarter. First Horizon Advisors Inc. lifted its position in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares in the last quarter. Icon Wealth Advisors LLC boosted its stake in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares during the last quarter. Foyston Gordon & Payne Inc purchased a new position in ICON Public during the 3rd quarter valued at approximately $11,672,000. Finally, GAMMA Investing LLC increased its stake in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.